Literature DB >> 315288

Studies on the nature of heat-labile anti-complementary activity in normal human serum.

R D Soltis, D Hasz, M J Morris, I D Wilson.   

Abstract

Heat-labile anti-complementary activity (ACA) appears in normal human serum during storage or heating as endogenous haemolytic activity disappears. Following gel filtration of unheated serum, two peaks of heat-labile ACA are present. The ACA of both whole and fractionated serum has previously been attributed to the presence of heat-labile immunoglobulin aggregates or immune complexes. Our data demonstrate that the heavy peak of ACA obtained by gel filtration does not bind to 125I-C1q or to Raji cells, and that its effect is abolished to C1INH, suggesting that it represents C1 rather than immunoglobulin aggregates or immune complexes. The lighter peak of ACA in fractionated serum has the functional characteristics of C1s and free C1s is demonstrable in fractions containing this activity. The ACA of whole serum likewise has functional characteristics of C1. The anti-complementary effect of C1 on guinea-pig complement would not be evident in the complement fixation assay until most endogenous haemolytic activity in human serum has been inactivated, either by heat or by storage. C1INH only partially inhibits this ACA in serum or in solutions containing isolated C1 in high concentrations. These observations indicate that heat-labile ACA in whole or fractionated sera is due to the presence of C1 and C1s and that this activity cannot be taken as evidence for the presence of immune complexes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 315288      PMCID: PMC1537798     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  20 in total

1.  The enhancement of the haemolytic activity of the first component of complement by trasylol.

Authors:  J M Delage; J Simard; G Lehner-netsch
Journal:  Immunology       Date:  1976-10       Impact factor: 7.397

2.  Observations on a pro-esterase associated with partially purified first component of human complement (C'1).

Authors:  I H LEPOW; O D RATNOFF; F S ROSEN; L PILLEMER
Journal:  Proc Soc Exp Biol Med       Date:  1956-05

3.  Immune complexes in ulcerative colitis and Crohn's disease.

Authors:  H J Hodgson; B J Potter; D P Jewell
Journal:  Clin Exp Immunol       Date:  1977-08       Impact factor: 4.330

4.  Anticomplementary activity of sera from patients with connective tissue disease and normal subjects.

Authors:  J P Castanedo; R C Williams
Journal:  J Lab Clin Med       Date:  1967-02

5.  Detection of circulating anticomplementary factors in chronic lung diseases.

Authors:  A M Hilton; M Moore; J M Howat
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

6.  The first complement component: evidence for an equilibrium between C1s free in serum and C1s bound in the C1 complex.

Authors:  R M Bartholomew; A F Esser
Journal:  J Immunol       Date:  1977-12       Impact factor: 5.422

7.  C1 inactivator inhibition by plasmin.

Authors:  P C Harpel
Journal:  J Clin Invest       Date:  1970-03       Impact factor: 14.808

8.  Studies on the activation of a proesterase associated with partially purified first component of human complement.

Authors:  I H LEPOW; O D RATNOFF; L R LEVY
Journal:  J Exp Med       Date:  1958-03-01       Impact factor: 14.307

9.  The conversion of C'IS to C'1 esterase by plasmin and trypsin.

Authors:  O D Ratnoff; G B Naff
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  Demonstration and quantitation of activation of the first component of complement in human serum.

Authors:  R J Ziccardi; N R Cooper
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

View more
  3 in total

1.  Candida albicans Shaving to Profile Human Serum Proteins on Hyphal Surface.

Authors:  Elvira Marín; Claudia M Parra-Giraldo; Carolina Hernández-Haro; María L Hernáez; César Nombela; Lucía Monteoliva; Concha Gil
Journal:  Front Microbiol       Date:  2015-12-08       Impact factor: 5.640

2.  Brugia malayi microfilariae adhere to human vascular endothelial cells in a C3-dependent manner.

Authors:  Jan-Hendrik Schroeder; David McCarthy; Tadge Szestak; Darren A Cook; Mark J Taylor; Alister G Craig; Charlotte Lawson; Rachel A Lawrence
Journal:  PLoS Negl Trop Dis       Date:  2017-05-08

3.  Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.

Authors:  Gergely Tibor Kozma; Tamás Mészáros; Tamás Bakos; Mark Hennies; Dániel Bencze; Barbara Uzonyi; Balázs Győrffy; Edward Cedrone; Marina A Dobrovolskaia; Mihály Józsi; János Szebeni
Journal:  Front Immunol       Date:  2021-04-28       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.